GLP-1 coverage for weight loss remains one of the most confusing areas in American healthcare. Some plans cover Wegovy with a $25 copay. Others exclude every anti-obesity medication entirely. This guide maps the terrain so you know what to expect from your specific plan type.
Disclosure: Some links on this page are affiliate links. This doesn't affect our coverage analysis. Information current as of May 2026.
Coverage by Plan Type
| Plan Type | Weight Loss GLP-1 Coverage | Prior Auth? | Typical Copay |
|---|---|---|---|
| Large Employer (self-insured) | Varies widely — ~40-50% cover AOMs | Almost always | $25–$150 |
| Small Employer | Less likely — cost pressure excludes AOMs | Yes | $50–$200+ |
| ACA Marketplace | Not mandated; varies by state/plan | Yes | Varies |
| Medicare Part D | Expanding — BALANCE Model covers Wegovy for cardiovascular risk | Yes | ~$50/mo cap |
| Medicaid | State-by-state; growing but inconsistent | Varies | $0–$10 |
| Tricare | Limited — covers for diabetes; weight loss varies | Yes | $0–$50 |
| VA | Available through VA formulary for eligible veterans | Yes | $0–$15 |
The Diabetes vs. Weight Loss Distinction
This is the single most important thing to understand about GLP-1 coverage: insurance plans treat diabetes and weight loss differently.
- For Type 2 diabetes: Ozempic and Mounjaro are broadly covered by most insurance plans. They're considered essential diabetes medications.
- For weight loss: Wegovy and Zepbound have much more limited coverage. Many plans explicitly exclude "anti-obesity medications" (AOMs) from their formulary.
Same drug, same active ingredient, different indication — different coverage. Semaglutide prescribed as Ozempic for diabetes? Covered. Semaglutide prescribed as Wegovy for weight loss? Maybe not.
Medicare's BALANCE Model
In December 2025, CMS announced the BALANCE Model (Building Access to Long-term Anti-Obesity Needs through Coverage Enhancement). This is a significant expansion:
Medicare will cover Wegovy for beneficiaries with established cardiovascular disease and obesity or overweight, with a monthly copay cap around $50. Full Part D coverage is expected to begin January 2027. This is the first time Medicare has covered an anti-obesity medication at scale.
How to Check Your Coverage
- Check your formulary: Call the number on your insurance card or log into your plan portal. Search for "semaglutide" or "Wegovy" specifically.
- Ask about exclusions: Specifically ask: "Does my plan exclude anti-obesity medications?" Some plans cover GLP-1s for diabetes but explicitly exclude them for weight loss.
- Review prior authorization requirements: Even if covered, you'll almost certainly need prior authorization. Ask what documentation is required.
- Check step therapy: Some plans require you to try (and fail) other weight loss interventions before approving GLP-1s.
- Understand your tier: GLP-1s are usually Tier 4 or Specialty tier, meaning higher copays even when covered.
If Your Insurance Doesn't Cover GLP-1s
You have several options beyond paying brand-name list price:
Manufacturer Savings Programs
Novo Nordisk and Eli Lilly both offer savings cards that can reduce costs to $25–$500/month for commercially insured patients. These don't work with Medicare or Medicaid.
Compounded Alternatives
Cash-pay compounded semaglutide and tirzepatide programs bypass insurance entirely. Prices range from $130–$300/month depending on the provider.
Brand-Name Telehealth
Some telehealth providers specialize in helping patients access brand-name GLP-1s through insurance, including managing the prior authorization process.
Prior Authorization: The Process
Prior authorization (PA) is the step where your insurance company reviews whether you meet their criteria before approving coverage. For GLP-1 weight loss medications, PA approval rates vary but many patients do get approved on the first or second attempt.
Common PA requirements include:
- BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
- Documentation of previous weight loss attempts (diet, exercise, behavioral)
- Letter of medical necessity from your prescribing provider
- Sometimes: documented failure of other weight loss medications first (step therapy)
A denied prior authorization isn't the end. You can appeal — and appeal success rates for GLP-1s are meaningful. Ask your provider to file a formal appeal with additional clinical documentation. Many denials are overturned on the first or second appeal.
State Mandates to Watch
Several states are considering or have passed legislation requiring insurance coverage of anti-obesity medications. This is a rapidly evolving area — check your state's current requirements. California and North Dakota have been among the states pushing coverage mandates forward.
- GLP-1 coverage for weight loss varies dramatically by plan type and employer
- Diabetes coverage (Ozempic/Mounjaro) is much broader than weight loss coverage (Wegovy/Zepbound)
- Medicare BALANCE Model expanding Wegovy access — full Part D coverage expected January 2027
- Prior authorization is almost universal — prepare documentation before applying
- If denied: appeal. Success rates are meaningful, especially with strong clinical documentation
- No insurance? Compounded options from $130–$200/month bypass the coverage question entirely
Insurance coverage information is general guidance — verify with your specific plan. This is not insurance or medical advice.